Geographic Atrophy

Dr. David Chin Yee describes how to spot early signs of geographic atrophy and explores promising new therapies that may slow progression and improve vision.

At EyeCon 2024, Dr. Adam S. Wenick led a symposium on geographic atrophy, covering diagnosis, FDA-approved treatments, and key clinician considerations through case presentations by Dr. Leonard Messner.

By identifying progressive GA earlier, primary eye care providers can make timely referrals and save patients’ visual function.

Understanding the latest innovative technologies.

Comanagement is a key component for treatment of disease.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

Utilizing artificial intelligence may provide feasibility assessments, data-driven protocol design, and cost reduction opportunities.

Apellis will seek re-examination from the CHMP following the opinion, according to a news release.

The company expects enrollment of the GAZE phase 1, open-label clinical trial, to begin in the second half of 2024.

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Real-world insights can clear the path to trends and strategies to meet patients’ needs.

Emily Chew, MD, who won this year's Proctor Award, outlines her presentation on preparing for estimated doubling of age-related macular degeneration cases in the next 25 years at ARVO 2024.

The company reported that statistically significant data was found supporting ANX007’s ability to provide vision loss protection in patients with geographic atrophy.

Mary Beth Yackey, OD, and Michael Javaheri, MD, share their perspectives on the modernization of geographic atrophy identification and treatment.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

Early detection of incipient geographic atrophy is critical to identify patients at greatest risk of progression and who may benefit most from newly approved complement inhibition therapies.

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The ANX007 global pivotal program is the first to use vision preservation as a primary outcome measure in GA.

Catch up on a few of the top stories from Modern Retina in 2023.

A study surveying retina specialists found surprising results in therapy preference.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

A multicenter study in Japan examined patients to understand geographic atrophy characteristics and progression rate.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

The first approved GA treatment leaves room for additional therapies.

Optometry Times sat down with Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, to discuss his upcoming presentations at AAOpt.